Schedule 13G ownership disclosure

NLS PHARMACEUTICS LTD

Common Shares, par value CHF 0.02 per share · CUSIP: H57830137

Event date: 2024-12-31

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Lind Global Fund II LP

    Shares: 59,780 · Class: 4.9%

  • Lind Global Partners II LLC

    Shares: 59,780 · Class: 4.9%

  • EASTON JEFF

    Shares: 59,780 · Class: 4.9%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000929638-25-000804
Form type
SCHEDULE 13G/A
Filer
Lind Global Fund II LP
CIK
CIK 1871665
Filed
Feb 14, 2025
Reporting period
Dec 31, 2024
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub